why choose us

First received: November 07, 2023

Clinical Trial: Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-Small Cell Lung Cancer (NSCLC)

Study Type: INTERVENTIONAL


Official Title: Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Brief Summary: This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.

Read more